Busulfan is a medication used to manage and treat allogeneic hematopoietic progenitor cell transplantation, specifically for patients with chronic myelogenous leukemia. It is in the antineoplastic class of drugs, and it is defined as an alkylating agent. This activity reviews the indications, action, and contraindications for busulfan as a valuable agent in the therapy for allogeneic hematopoietic progenitor cell transplantation, specifically for patients with chronic myelogenous leukemia and other disorders when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions pertinent for members of the interprofessional healthcare team in the management of patients with chronic myelogenous leukemia and other related conditions.

**Objectives:**
- Identify the mechanism of action of busulfan.
- Describe the adverse effects profile of busulfan. 
- Review select appropriate monitoring of busulfan. 
- Summarize team strategies for improving care coordination and communication to advance busulfan and improve outcomes.